Analysis of One Case of purpura fulminans Induced by Gefitinib Tablets

doi:10.19803/j.1672-8629.2020.07.12

Abstract

Abstract: Objective To explore the treatment of purpura fulminans induced by gefitinib tablets, so as to provide reference for clinical rational use of drugs. Methods The mechanism and countermeasures of purpura fulminans induced by gefitinib tablets were studied by literature retrieval and analyzing the treatment process of a patient. Results 5 days after taking gefitinib tablets, the patient was diagnosed with purpura fulminans. The drug was stopped immediately so that the symptoms on the patient’s skin were relieved gradually via treatment with vitamin C, calcium gluconate, methylprednisolone sodium succinate and other supportive treatment. Conclusion Gefitinib-induced purpura fulminans should be stopped immediately, and the EGFR-TKI should be given again after the adverse reactions have improved.

Key words: gefitinib, purpura fulminans, analysis, adenocarcinoma of lung, adverse drug reaction

CLC Number:

R994.11

FAN Pengli, LU Lele, WANG Yimeng, LIU Yinping. Analysis of One Case of purpura fulminans Induced by Gefitinib Tablets[J]. Chinese Journal of Pharmacovigilance, 2020, 17(7): 441-443.

References

[1] 杨同江,王全亮,解李丽.吉非替尼的临床应用研究[J].药学研究,2017,36(4):243-245.
[2] 中国抗癌协会肺癌专业委员会.EGFR-TKI不良反应管理专家共识[J].中国肺癌杂志,2019,22(2): 57-81.
[3] Rahman AF,Korashy HM,Kassem MG.Gefitinib[J]. Profiles Drug Subst Excip Relat Methodol, 2014(39): 239-64.
[4] 夏惠红. 82例吉非替尼不良反应的文献分析[J].中国药物警戒,2016,13(2):98-102.
[5] Kurokawa I,Endo K,HirabayashiM. Purpuric drug eruption possibly due to gefitinib (Iressa)[J]. Int J Dermatol, 2005,44(2):167-168.
[6] Sheen YS,Hsiao CH,Chu CY.Severe purpuric xerotic dermatitis associated with gefitinib therapy[J]. Arch Dermatol, 2008, 144(2):269-70.
[7] Shih HC, Hsiao YP, Wu MF, et al.Gefitinib-induced acute generalized exanthematous pustulosis in two patients with advanced non-small-cell lung cancer[J]. Br J Dermatol, 2006,155(5):1101-1102.
[8] 马天,李斌,刘业强,等. 吉非替尼引起头皮糜烂性脓疱性皮病样皮疹[J]. 临床皮肤科杂志, 2018, 47(2): 100-102.
[9] 于凡,王燕婴,黄月华,等. 表皮生长因子受体酪氨酸激酶抑制剂致间质性肺炎后再用同类药物治疗一例并文献复习[J]. 肿瘤研究与临床, 2019, 31(10): 698-700.
[10] 姜军,刘昱君,赵君慧. 吉非替尼致毛发变黑1例[J]. 临床肿瘤学杂志, 2016, 21(7): 669-670.
[11] 俞燕华. 吉非替尼致神经性耳聋1例[J]. 医药导报, 2019,38(8):1098-1099.
[12] Common Terminology Criteria for Adverse Events (CTCAE)v5.0 .https://ctep.cancer.gov/protocoldevelopment/electronic_applicati-ons/docs/CTCAE_v5_Quick_Reference_5x7.pdf.Publish Date:2017-11-27.
[13] Naranjo CA, Busto U, Sellers EM, et al.A method for estimating the probability of adverse drug reactions[J]. Clin Pharmacol Ther,1981,30(2):239-245.
[14] 犹月. 诺氏评估量表法在对乙酰氨基酚致横纹肌溶解综合征中的应用价值[J]. 中国医院用药评价与分析, 2019, 19(2): 240-242.
[15] Jost M, Kari C, Rodeck U.The EGF receptor-an essential regulator of multiple epidermal functions[J]. Eur J Demmt, 2000, 10(7):505-510.
[16] Perez-Soler R, Chachoua A, Hammond LA, et al.Determinant of tumor response and survival with erlotinib in patients with non-small-cell lung cancer[J]. J Clin Oncol, 2004, 22(16):3238-3247.
[17] Petrelli F, Borgonovo K, Cabiddu M, et a1. Relationship between skin rash and outcome in non-small-cell lung cancer patients treated with anti-EGFR tyrosine kinase inhibitors: a literature-based meta-analysis of 24 trials[J]. Lung Cancer, 2012, 78(1): 8-15.
[18] 支修益. 表皮生长因子受体酪氨酸激酶抑制剂治疗非小细胞肺癌相关不良反应研究进展[J]. 药物不良反应杂志, 2013,15(3): 152-156.
[19] 朱愿超,常建民,胡欣,等. 表皮生长因子受体抑制剂引的皮肤不良反应临床表现及防治[J]. 药物不良反应杂志, 2018,20(3): 220-225.